Tag Archives: Michael Higgins

Marinus (MRNS) Gets a Buy Rating from Ladenburg Thalmann & Co.

Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Marinus (MRNS – Research Report) today and set a price target of $5.00. The company’s shares closed last Monday at $1.09, close to its 52-week low of $0.77.

Eiger Biopharmaceuticals (EIGR) Receives a Buy from Ladenburg Thalmann & Co.

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Eiger Biopharmaceuticals (EIGR – Research Report), with a price target of $28.00. The company’s shares closed last Monday at $10.97. According to TipRanks.com,

Ladenburg Thalmann & Co. Sticks to Its Buy Rating for Novavax (NVAX)

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Novavax (NVAX – Research Report), with a price target of $27.50. The company’s shares closed last Monday at $4.50, close to its 52-week

SCYNEXIS (SCYX) Gets a Buy Rating from Ladenburg Thalmann & Co.

Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on SCYNEXIS (SCYX – Research Report) today and set a price target of $6.00. The company’s shares closed last Monday at $1.35. According to TipRanks.com, Higgins is ranked 0

Ladenburg Thalmann & Co. Keeps a Hold Rating on Savara Inc (SVRA)

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. reiterated a Hold rating on Savara Inc (SVRA – Research Report), with a price target of $1.00. The company’s shares closed last Monday at $1.03, close to its

Ladenburg Thalmann & Co. Sticks to Their Buy Rating for Marinus (MRNS)

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. reiterated a Buy rating on Marinus (MRNS – Research Report), with a price target of $5.00. The company’s shares closed last Monday at $1.64, close to its 52-week